| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6192409 | Journal of Thoracic Oncology | 2016 | 32 Pages |
Abstract
This retrospective registry study suggested that LSD is an alternative to SND for selected patients with c-stage I or II NSCLC. Future prospective studies are warranted to determine whether LSD is applicable and provides clinical benefit for the general population of patients with c-stage I or II NSCLC.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Tomoyuki MD, Etsuo PhD, Kohei MD, Masahiro MD, Hisao MD, Katsuyuki MD, Kazuhisa MD, Hirotoshi MD, Hideo MD, Hiroshi MD, Hirohito MD, Meinoshin MD, Ichiro MD,